お見積

サンプルお申込み

お問い合わせ

今すぐ購入

※ご注文方法：お問い合わせフォームまたはメールにてご連絡ください。
支払方法：「銀行振込」の場合， 注文の確認後、ご指定のメールアドレスに電子版の請求書をお送りいたしますので、電子版の請求書の記載事項に従って送金操作を行ってください。
※納期：原則として、受注後2～4営業日以内に発送いたします。 但し、日本語版が必要な場合は、受注後8～10営業日となります。 お客様のニーズに合わせて、事前にご注文のスケジュールをお立てください。

本報告書は生物学的製剤CDMO市場規模の世界市場の概要を紹介します。2020~2024年の歴史的な市場収益データ、2025年の予想、および2031年までのCAGRの予測を含む世界市場動向の分析。レポートは生物学的製剤CDMOの主要メーカーを詳細に分析し、地域別・国別の収益プロフィールを明らかにしています。 本レポートでは特に、主要地域/国別のセグメントとサブセグメントについて、将来の市場ポテンシャルの探索と予測に焦点を当てています。 複数の地域にわたる包括的なデータと市場価値分析により、読者は包括的かつ詳細な市場洞察を得ることができます。

世界の生物学的製剤CDMO市場の主な参加者である企業概要、収益、粗利益率、ポートフォリオ、地理的位置、重要な発展について、次のパラメータに基づいて説明します。レポートは生物学的製剤CDMOのメーカー、地域、種類と端末業界の角度から世界と主要地域の市場現状と将来性を研究した、このレポートでは、世界と主要地域のトップメーカーを分析し、タイプとアプリケーション/端末業界別に生物学的製剤CDMO市場を分類しています。本研究に含まれる主な企業は：Lonza、Catalent、Samsung Biologics、FUJIFILM Diosynth Biotechnologies、Boehringer Ingelheim、WuXi Biologics、Recipharm、Thermo Fisher Scientific、AGC Biologics、Rentschler Biopharma、KBI Biopharma、Siegfried、Aenova Group、GenScript、ProBioGen、Northway Biotech、3P Biopharmaceuticals

地域別市場区分、地域別分析は以下の通り：
    アメリカとカナダ
    中国
    アジア
    ヨーロッパ
    中東、アフリカ、ラテンアメリカ

タイプ別市場セグメント：
    Cell and Gene Therapies
    Antibodies
    Vaccines
    Other

用途別の市場セグメント：
    SMBs
    Large Companies

本レポートの詳細内容
世界の生物学的製剤CDMO市場の現状と将来について、グローバルの主要地域を中心に包括的に分析しています。 当レポートでは、多角的な分析を通じて、市場プレイヤー、地域分布、生物学的製剤CDMOタイプ、最終用途アプリケーションなどの主要分野を掘り下げ、読者に包括的な市場洞察を提供しています。 レポートは主要企業の生物学的製剤CDMO収益、市場シェア、業界ランキング、2020年から2025年までのデータに焦点を当てています。世界の生物学的製剤CDMO市場における主要なステークホルダーの特定、最近の動向とセグメント収益に基づいて競争状況と市場ポジショニングの分析。また、当レポートでは、世界市場の主要プレイヤーを特定し、プロファイルを作成するとともに、生物学的製剤CDMO市場を綿密に分類・応用することで、読者が市場構造とダイナミクスをより正確に把握できるようにし、十分な情報に基づいた意思決定と戦略立案に強力なサポートを提供しています。

生物学的製剤CDMOのレポートは2020年から2031年までのタイプ別およびアプリケーション別、収益、成長率別のセグメントデータを分析します。収益、予測成長傾向、アプリケーション、およびエンドユーザー業界の市場規模を評価および予測します。

章の概要
第1章：生物学的製剤CDMOのレポートの報告範囲、各セグメントの市場規模、将来の開発可能性などを含む、さまざまな市場セグメント（製品タイプ、用途など）のエグゼクティブサマリーを紹介します。市場の現状と、短期から中期、および長期的な進化の可能性をハイレベルに見ることができます。（2020～2031）
第2章：生物学的製剤CDMOの世界及び地域レベルでの売上高。各地域とその主要国の市場規模と発展の可能性を定量的に分析し、世界各国の市場発展、今後の発展展望、市場空間、生産能力などを紹介する。また、市場ダイナミクス、市場の最新動向、市場の推進要因と制限要因、業界企業が直面する課題とリスク、業界の関連政策の分析などを紹介しています。（2020～2031）
第3章生物学的製剤CDMO企業の競争状況、収益、市場シェアと業界ランキング、最新の開発計画、合併・買収情報などの詳細分析。（2020～2031）
第4章：各市場セグメントの収益と開発の可能性をカバーし、種類別のさまざまな市場セグメントの分析を提供し、読者がさまざまな市場セグメントでブルーオーシャン市場を見つけるのに役立ちます。（2020～2025）
第5章：生物学的製剤CDMOの各市場セグメントの収益と開発の可能性をカバーするアプリケーション別のさまざまな市場セグメントの分析を提供し、読者がさまざまな下流市場でブルーオーシャン市場を見つけるのに役立ちます。（2020～2031）
第6章：北米（米国、カナダ）のタイプ別、アプリケーション別、国別、各セグメントの収益。（2020～2031）
第7章：ヨーロッパのタイプ別、アプリケーション別、国別、各セグメントの収益。（2020～2031）
第8章：中国の種類別、および用途別、各セグメントの収益。（2020～2031）
第9章アジア（中国を除く）の種類別、用途別、地域別、セグメントごとの収益。（2020～2031）
第10章：中東、アフリカ、ラテンアメリカの種類別、アプリケーション別、国別、各セグメントの収益。（2020～2031）
第11章：生物学的製剤CDMOの主要企業の概要を提供し、製品の説明と仕様、生物学的製剤CDMOの収益、粗利益率、最近の展開など、市場の主要企業の基本状況を詳細に紹介します。（2020～2025）
第12章：アナリストの見解/結論

Valued at US$ 28160 million in 2024, the global Biological Drug CDMO market is forecast to reach US$ 59060 million by 2030, at a CAGR of 13.1% during the forecast period.
Biological drug CDMO (Contract Development and Manufacturing Organization) is a company that specializes in the development and manufacturing of biological drugs. Biological drugs are complex molecules that are produced from living cells, and they include a wide range of products such as vaccines, monoclonal antibodies, and cell therapies.
Increasing Demand for Biologics: The rising demand for biopharmaceuticals, including monoclonal antibodies, recombinant proteins, and gene therapies, is a significant driver. Biologics are increasingly becoming a focus for drug development due to their effectiveness in treating various diseases.
Cost-Effective Outsourcing: Outsourcing to CDMOs allows pharmaceutical and biotech companies to reduce capital expenditures, mitigate risks, and achieve cost savings. CDMOs offer specialized facilities and expertise, allowing clients to avoid the need for extensive in-house infrastructure.
Strategic Partnerships and Collaborations: Pharmaceutical and biotech companies increasingly engage in strategic partnerships with CDMOs to access specialized capabilities, share development risks, and benefit from the CDMO's expertise in specific technologies or therapeutic areas.

To meet the growing demand for biopharmaceuticals, CDMOs are investing in expanding their biomanufacturing capacities. This includes the construction of new facilities and the acquisition of advanced technologies to increase production capabilities.
The increasing interest and investment in cell and gene therapies have led to a rise in demand for CDMOs offering services in this area. Companies are seeking expertise in cell line development, viral vector production, and other specialized services related to advanced therapies.
Biopharmaceutical CDMOs are expanding their global presence to cater to the needs of a geographically diverse client base. This includes establishing facilities in key regions and forming strategic partnerships to enhance their global reach.
CDMOs are expanding their service offerings to provide integrated solutions covering the entire biopharmaceutical development and manufacturing lifecycle. This integrated approach aims to streamline processes and accelerate time to market for clients.
Report Includes
This report presents an overview of global market for Biological Drug CDMO market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Biological Drug CDMO, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Biological Drug CDMO, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Biological Drug CDMO revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Biological Drug CDMO market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Biological Drug CDMO revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Lonza, Catalent, Samsung Biologics, FUJIFILM Diosynth Biotechnologies, Boehringer Ingelheim, WuXi Biologics, Recipharm, Thermo Fisher Scientific, AGC Biologics, Rentschler Biopharma, etc.

Market Segmentation
By Company
    Lonza
    Catalent
    Samsung Biologics
    FUJIFILM Diosynth Biotechnologies
    Boehringer Ingelheim
    WuXi Biologics
    Recipharm
    Thermo Fisher Scientific
    AGC Biologics
    Rentschler Biopharma
    KBI Biopharma
    Siegfried
    Aenova Group
    GenScript
    ProBioGen
    Northway Biotech
    3P Biopharmaceuticals

Segment by Type
    Cell and Gene Therapies
    Antibodies
    Vaccines
    Other

Segment by Application
    SMBs
    Large Companies

By Region
    North America
        United States
        Canada
    Asia-Pacific
        China
        Japan
        South Korea
        Southeast Asia
        India
        Australia
        Rest of Asia
    Europe
        Germany
        France
        U.K.
        Italy
        Russia
        Nordic Countries
        Rest of Europe
    Latin America
        Mexico
        Brazil
        Rest of South America
    Middle East & Africa
        Turkey
        Saudi Arabia
        UAE
        Rest of MEA

Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Biological Drug CDMO in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Biological Drug CDMO companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Biological Drug CDMO revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions

List of Tables
 Table 1. Global Biological Drug CDMO Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
 Table 2. Key Players of Cell and Gene Therapies
 Table 3. Key Players of Antibodies
 Table 4. Key Players of Vaccines
 Table 5. Key Players of Other
 Table 6. Global Biological Drug CDMO Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
 Table 7. Global Biological Drug CDMO Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
 Table 8. Global Biological Drug CDMO Market Size by Region (2019-2024) & (US$ Million)
 Table 9. Global Biological Drug CDMO Market Share by Region (2019-2024)
 Table 10. Global Biological Drug CDMO Forecasted Market Size by Region (2025-2030) & (US$ Million)
 Table 11. Global Biological Drug CDMO Market Share by Region (2025-2030)
 Table 12. Biological Drug CDMO Market Trends
 Table 13. Biological Drug CDMO Market Drivers
 Table 14. Biological Drug CDMO Market Challenges
 Table 15. Biological Drug CDMO Market Restraints
 Table 16. Global Biological Drug CDMO Revenue by Players (2019-2024) & (US$ Million)
 Table 17. Global Biological Drug CDMO Market Share by Players (2019-2024)
 Table 18. Global Top Biological Drug CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biological Drug CDMO as of 2023)
 Table 19. Global Biological Drug CDMO Industry Ranking 2022 VS 2023
 Table 20. Global 5 Largest Players Market Share by Biological Drug CDMO Revenue (CR5 and HHI) & (2019-2024)
 Table 21. Global Key Players of Biological Drug CDMO, Headquarters and Area Served
 Table 22. Global Key Players of Biological Drug CDMO, Product and Application
 Table 23. Global Key Players of Biological Drug CDMO, Date of Enter into This Industry
 Table 24. Mergers & Acquisitions, Expansion Plans
 Table 25. Global Biological Drug CDMO Market Size by Type (2019-2024) & (US$ Million)
 Table 26. Global Biological Drug CDMO Revenue Market Share by Type (2019-2024)
 Table 27. Global Biological Drug CDMO Forecasted Market Size by Type (2025-2030) & (US$ Million)
 Table 28. Global Biological Drug CDMO Revenue Market Share by Type (2025-2030)
 Table 29. Global Biological Drug CDMO Market Size by Application (2019-2024) & (US$ Million)
 Table 30. Global Biological Drug CDMO Revenue Market Share by Application (2019-2024)
 Table 31. Global Biological Drug CDMO Forecasted Market Size by Application (2025-2030) & (US$ Million)
 Table 32. Global Biological Drug CDMO Revenue Market Share by Application (2025-2030)
 Table 33. North America Biological Drug CDMO Market Size by Type (2019-2024) & (US$ Million)
 Table 34. North America Biological Drug CDMO Market Size by Type (2025-2030) & (US$ Million)
 Table 35. North America Biological Drug CDMO Market Size by Application (2019-2024) & (US$ Million)
 Table 36. North America Biological Drug CDMO Market Size by Application (2025-2030) & (US$ Million)
 Table 37. North America Biological Drug CDMO Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
 Table 38. North America Biological Drug CDMO Market Size by Country (2019-2024) & (US$ Million)
 Table 39. North America Biological Drug CDMO Market Size by Country (2025-2030) & (US$ Million)
 Table 40. Europe Biological Drug CDMO Market Size by Type (2019-2024) & (US$ Million)
 Table 41. Europe Biological Drug CDMO Market Size by Type (2025-2030) & (US$ Million)
 Table 42. Europe Biological Drug CDMO Market Size by Application (2019-2024) & (US$ Million)
 Table 43. Europe Biological Drug CDMO Market Size by Application (2025-2030) & (US$ Million)
 Table 44. Europe Biological Drug CDMO Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
 Table 45. Europe Biological Drug CDMO Market Size by Country (2019-2024) & (US$ Million)
 Table 46. Europe Biological Drug CDMO Market Size by Country (2025-2030) & (US$ Million)
 Table 47. China Biological Drug CDMO Market Size by Type (2019-2024) & (US$ Million)
 Table 48. China Biological Drug CDMO Market Size by Type (2025-2030) & (US$ Million)
 Table 49. China Biological Drug CDMO Market Size by Application (2019-2024) & (US$ Million)
 Table 50. China Biological Drug CDMO Market Size by Application (2025-2030) & (US$ Million)
 Table 51. Asia Biological Drug CDMO Market Size by Type (2019-2024) & (US$ Million)
 Table 52. Asia Biological Drug CDMO Market Size by Type (2025-2030) & (US$ Million)
 Table 53. Asia Biological Drug CDMO Market Size by Application (2019-2024) & (US$ Million)
 Table 54. Asia Biological Drug CDMO Market Size by Application (2025-2030) & (US$ Million)
 Table 55. Asia Biological Drug CDMO Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
 Table 56. Asia Biological Drug CDMO Market Size by Region (2019-2024) & (US$ Million)
 Table 57. Asia Biological Drug CDMO Market Size by Region (2025-2030) & (US$ Million)
 Table 58. Middle East, Africa, and Latin America Biological Drug CDMO Market Size by Type (2019-2024) & (US$ Million)
 Table 59. Middle East, Africa, and Latin America Biological Drug CDMO Market Size by Type (2025-2030) & (US$ Million)
 Table 60. Middle East, Africa, and Latin America Biological Drug CDMO Market Size by Application (2019-2024) & (US$ Million)
 Table 61. Middle East, Africa, and Latin America Biological Drug CDMO Market Size by Application (2025-2030) & (US$ Million)
 Table 62. Middle East, Africa, and Latin America Biological Drug CDMO Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
 Table 63. Middle East, Africa, and Latin America Biological Drug CDMO Market Size by Country (2019-2024) & (US$ Million)
 Table 64. Middle East, Africa, and Latin America Biological Drug CDMO Market Size by Country (2025-2030) & (US$ Million)
 Table 65. Lonza Company Details
 Table 66. Lonza Business Overview
 Table 67. Lonza Biological Drug CDMO Product
 Table 68. Lonza Revenue in Biological Drug CDMO Business (2019-2024) & (US$ Million)
 Table 69. Lonza Recent Development
 Table 70. Catalent Company Details
 Table 71. Catalent Business Overview
 Table 72. Catalent Biological Drug CDMO Product
 Table 73. Catalent Revenue in Biological Drug CDMO Business (2019-2024) & (US$ Million)
 Table 74. Catalent Recent Development
 Table 75. Samsung Biologics Company Details
 Table 76. Samsung Biologics Business Overview
 Table 77. Samsung Biologics Biological Drug CDMO Product
 Table 78. Samsung Biologics Revenue in Biological Drug CDMO Business (2019-2024) & (US$ Million)
 Table 79. Samsung Biologics Recent Development
 Table 80. FUJIFILM Diosynth Biotechnologies Company Details
 Table 81. FUJIFILM Diosynth Biotechnologies Business Overview
 Table 82. FUJIFILM Diosynth Biotechnologies Biological Drug CDMO Product
 Table 83. FUJIFILM Diosynth Biotechnologies Revenue in Biological Drug CDMO Business (2019-2024) & (US$ Million)
 Table 84. FUJIFILM Diosynth Biotechnologies Recent Development
 Table 85. Boehringer Ingelheim Company Details
 Table 86. Boehringer Ingelheim Business Overview
 Table 87. Boehringer Ingelheim Biological Drug CDMO Product
 Table 88. Boehringer Ingelheim Revenue in Biological Drug CDMO Business (2019-2024) & (US$ Million)
 Table 89. Boehringer Ingelheim Recent Development
 Table 90. WuXi Biologics Company Details
 Table 91. WuXi Biologics Business Overview
 Table 92. WuXi Biologics Biological Drug CDMO Product
 Table 93. WuXi Biologics Revenue in Biological Drug CDMO Business (2019-2024) & (US$ Million)
 Table 94. WuXi Biologics Recent Development
 Table 95. Recipharm Company Details
 Table 96. Recipharm Business Overview
 Table 97. Recipharm Biological Drug CDMO Product
 Table 98. Recipharm Revenue in Biological Drug CDMO Business (2019-2024) & (US$ Million)
 Table 99. Recipharm Recent Development
 Table 100. Thermo Fisher Scientific Company Details
 Table 101. Thermo Fisher Scientific Business Overview
 Table 102. Thermo Fisher Scientific Biological Drug CDMO Product
 Table 103. Thermo Fisher Scientific Revenue in Biological Drug CDMO Business (2019-2024) & (US$ Million)
 Table 104. Thermo Fisher Scientific Recent Development
 Table 105. AGC Biologics Company Details
 Table 106. AGC Biologics Business Overview
 Table 107. AGC Biologics Biological Drug CDMO Product
 Table 108. AGC Biologics Revenue in Biological Drug CDMO Business (2019-2024) & (US$ Million)
 Table 109. AGC Biologics Recent Development
 Table 110. Rentschler Biopharma Company Details
 Table 111. Rentschler Biopharma Business Overview
 Table 112. Rentschler Biopharma Biological Drug CDMO Product
 Table 113. Rentschler Biopharma Revenue in Biological Drug CDMO Business (2019-2024) & (US$ Million)
 Table 114. Rentschler Biopharma Recent Development
 Table 115. KBI Biopharma Company Details
 Table 116. KBI Biopharma Business Overview
 Table 117. KBI Biopharma Biological Drug CDMO Product
 Table 118. KBI Biopharma Revenue in Biological Drug CDMO Business (2019-2024) & (US$ Million)
 Table 119. KBI Biopharma Recent Development
 Table 120. Siegfried Company Details
 Table 121. Siegfried Business Overview
 Table 122. Siegfried Biological Drug CDMO Product
 Table 123. Siegfried Revenue in Biological Drug CDMO Business (2019-2024) & (US$ Million)
 Table 124. Siegfried Recent Development
 Table 125. Aenova Group Company Details
 Table 126. Aenova Group Business Overview
 Table 127. Aenova Group Biological Drug CDMO Product
 Table 128. Aenova Group Revenue in Biological Drug CDMO Business (2019-2024) & (US$ Million)
 Table 129. Aenova Group Recent Development
 Table 130. GenScript Company Details
 Table 131. GenScript Business Overview
 Table 132. GenScript Biological Drug CDMO Product
 Table 133. GenScript Revenue in Biological Drug CDMO Business (2019-2024) & (US$ Million)
 Table 134. GenScript Recent Development
 Table 135. ProBioGen Company Details
 Table 136. ProBioGen Business Overview
 Table 137. ProBioGen Biological Drug CDMO Product
 Table 138. ProBioGen Revenue in Biological Drug CDMO Business (2019-2024) & (US$ Million)
 Table 139. ProBioGen Recent Development
 Table 140. Northway Biotech Company Details
 Table 141. Northway Biotech Business Overview
 Table 142. Northway Biotech Biological Drug CDMO Product
 Table 143. Northway Biotech Revenue in Biological Drug CDMO Business (2019-2024) & (US$ Million)
 Table 144. Northway Biotech Recent Development
 Table 145. 3P Biopharmaceuticals Company Details
 Table 146. 3P Biopharmaceuticals Business Overview
 Table 147. 3P Biopharmaceuticals Biological Drug CDMO Product
 Table 148. 3P Biopharmaceuticals Revenue in Biological Drug CDMO Business (2019-2024) & (US$ Million)
 Table 149. 3P Biopharmaceuticals Recent Development
 Table 150. Research Programs/Design for This Report
 Table 151. Key Data Information from Secondary Sources
 Table 152. Key Data Information from Primary Sources


List of Figures
 Figure 1. Global Biological Drug CDMO Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
 Figure 2. Global Biological Drug CDMO Market Share by Type: 2023 VS 2030
 Figure 3. Cell and Gene Therapies Features
 Figure 4. Antibodies Features
 Figure 5. Vaccines Features
 Figure 6. Other Features
 Figure 7. Global Biological Drug CDMO Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
 Figure 8. Global Biological Drug CDMO Market Share by Application: 2023 VS 2030
 Figure 9. SMBs Case Studies
 Figure 10. Large Companies Case Studies
 Figure 11. Biological Drug CDMO Report Years Considered
 Figure 12. Global Biological Drug CDMO Market Size (US$ Million), Year-over-Year: 2019-2030
 Figure 13. Global Biological Drug CDMO Market Size, (US$ Million), 2019 VS 2023 VS 2030
 Figure 14. Global Biological Drug CDMO Market Share by Region: 2023 VS 2030
 Figure 15. Global Biological Drug CDMO Market Share by Players in 2023
 Figure 16. Global Top Biological Drug CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biological Drug CDMO as of 2023)
 Figure 17. The Top 10 and 5 Players Market Share by Biological Drug CDMO Revenue in 2023
 Figure 18. North America Biological Drug CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 19. North America Biological Drug CDMO Market Share by Type (2019-2030)
 Figure 20. North America Biological Drug CDMO Market Share by Application (2019-2030)
 Figure 21. North America Biological Drug CDMO Market Share by Country (2019-2030)
 Figure 22. United States Biological Drug CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 23. Canada Biological Drug CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 24. Europe Biological Drug CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 25. Europe Biological Drug CDMO Market Share by Type (2019-2030)
 Figure 26. Europe Biological Drug CDMO Market Share by Application (2019-2030)
 Figure 27. Europe Biological Drug CDMO Market Share by Country (2019-2030)
 Figure 28. Germany Biological Drug CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 29. France Biological Drug CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 30. U.K. Biological Drug CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 31. Italy Biological Drug CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 32. Russia Biological Drug CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 33. Nordic Countries Biological Drug CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 34. China Biological Drug CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 35. China Biological Drug CDMO Market Share by Type (2019-2030)
 Figure 36. China Biological Drug CDMO Market Share by Application (2019-2030)
 Figure 37. Asia Biological Drug CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 38. Asia Biological Drug CDMO Market Share by Type (2019-2030)
 Figure 39. Asia Biological Drug CDMO Market Share by Application (2019-2030)
 Figure 40. Asia Biological Drug CDMO Market Share by Region (2019-2030)
 Figure 41. Japan Biological Drug CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 42. South Korea Biological Drug CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 43. China Taiwan Biological Drug CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 44. Southeast Asia Biological Drug CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 45. India Biological Drug CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 46. Australia Biological Drug CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 47. Middle East, Africa, and Latin America Biological Drug CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 48. Middle East, Africa, and Latin America Biological Drug CDMO Market Share by Type (2019-2030)
 Figure 49. Middle East, Africa, and Latin America Biological Drug CDMO Market Share by Application (2019-2030)
 Figure 50. Middle East, Africa, and Latin America Biological Drug CDMO Market Share by Country (2019-2030)
 Figure 51. Brazil Biological Drug CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 52. Mexico Biological Drug CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 53. Turkey Biological Drug CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 54. Saudi Arabia Biological Drug CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 55. Israel Biological Drug CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 56. GCC Countries Biological Drug CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 57. Lonza Revenue Growth Rate in Biological Drug CDMO Business (2019-2024)
 Figure 58. Catalent Revenue Growth Rate in Biological Drug CDMO Business (2019-2024)
 Figure 59. Samsung Biologics Revenue Growth Rate in Biological Drug CDMO Business (2019-2024)
 Figure 60. FUJIFILM Diosynth Biotechnologies Revenue Growth Rate in Biological Drug CDMO Business (2019-2024)
 Figure 61. Boehringer Ingelheim Revenue Growth Rate in Biological Drug CDMO Business (2019-2024)
 Figure 62. WuXi Biologics Revenue Growth Rate in Biological Drug CDMO Business (2019-2024)
 Figure 63. Recipharm Revenue Growth Rate in Biological Drug CDMO Business (2019-2024)
 Figure 64. Thermo Fisher Scientific Revenue Growth Rate in Biological Drug CDMO Business (2019-2024)
 Figure 65. AGC Biologics Revenue Growth Rate in Biological Drug CDMO Business (2019-2024)
 Figure 66. Rentschler Biopharma Revenue Growth Rate in Biological Drug CDMO Business (2019-2024)
 Figure 67. KBI Biopharma Revenue Growth Rate in Biological Drug CDMO Business (2019-2024)
 Figure 68. Siegfried Revenue Growth Rate in Biological Drug CDMO Business (2019-2024)
 Figure 69. Aenova Group Revenue Growth Rate in Biological Drug CDMO Business (2019-2024)
 Figure 70. GenScript Revenue Growth Rate in Biological Drug CDMO Business (2019-2024)
 Figure 71. ProBioGen Revenue Growth Rate in Biological Drug CDMO Business (2019-2024)
 Figure 72. Northway Biotech Revenue Growth Rate in Biological Drug CDMO Business (2019-2024)
 Figure 73. 3P Biopharmaceuticals Revenue Growth Rate in Biological Drug CDMO Business (2019-2024)
 Figure 74. Bottom-up and Top-down Approaches for This Report
 Figure 75. Data Triangulation
 Figure 76. Key Executives Interviewed